

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

CDK6 (D4S8S) Rabbit mAb

RRID:AB_2721897

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 13331, RRID:AB_2721897

Antibody Information

URL: http://antibodyregistry.org/AB_2721897

Proper Citation: Cell Signaling Technology Cat# 13331, RRID:AB_2721897

Target Antigen: CDK6

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: CDK6 (D4S8S) Rabbit mAb

Description: This monoclonal targets CDK6

Target Organism: monkey, human

Clone ID: D4S8S

Antibody ID: AB_2721897

Vendor: Cell Signaling Technology

Catalog Number: 13331

Record Creation Time: 20250820T070717+0000

Record Last Update: 20250821T013844+0000

Ratings and Alerts

No rating or validation information has been found for CDK6 (D4S8S) Rabbit mAb.

No alerts have been found for CDK6 (D4S8S) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Burbidge O, et al. (2025) Nanobodies restore stability to cancer-associated mutants of tumor suppressor protein p16INK4a. Structure (London, England : 1993).

Wang T, et al. (2025) Optochemical control of G1 cell cycle by regulating CDK4/6 degradation. iScience, 28(9), 113304.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Liu Z, et al. (2024) YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. iScience, 27(3), 109125.

Ichikawa S, et al. (2024) The cyclimids: Degron-inspired cereblon binders for targeted protein degradation. Cell chemical biology.

Liu I, et al. (2024) GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer cell.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. Cell reports, 43(5), 114134.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Yu M, et al. (2023) FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth. Cell reports, 42(8), 112886.

Wurm AA, et al. (2023) Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. Cell reports. Medicine, 4(10), 101200.

Jovanovi? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Chen PJ, et al. (2023) Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis. British journal of pharmacology.

Baldelli E, et al. (2022) Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach. *Cell reports methods*, 2(8), 100271.

Ryu S, et al. (2021) Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. *Current research in chemical biology*, 1.

Parrish PCR, et al. (2021) Discovery of synthetic lethal and tumor suppressor paralog pairs in the human genome. *Cell reports*, 36(9), 109597.

Enrico TP, et al. (2021) Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2. *eLife*, 10.

George J, et al. (2021) RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. *Cell reports*, 37(5), 109934.

D'Oto A, et al. (2021) KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. *Nature communications*, 12(1), 7204.

Cornell L, et al. (2019) MicroRNA-Mediated Suppression of the TGF- β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. *Cell reports*, 26(10), 2667.